Skip to Content
Merck
  • Inhibition of melanogenic activity by 4,4'-dihydroxybiphenyl in melanoma cells.

Inhibition of melanogenic activity by 4,4'-dihydroxybiphenyl in melanoma cells.

Biological & pharmaceutical bulletin (2006-01-06)
Jae Kyung No, You Jung Kim, Jun Sik Lee, Hae Young Chung
ABSTRACT

In our previous study, we showed that 4,4'-dihydroxybiphenyl (44'-BP) reduced melanin content via the inhibition of tyrosinase. In the current study, we utilized 44'-BP treated B16 melanoma cells (B16 cells) to measure several key cellular parameters known to be involved in melanogenic activity. Included in these measurements were tyrosinase and microphthalmia transcription factor (MITF) protein levels, cyclic AMP levels, protein kinase A (PKA) activation, and reduced glutathione (GSH) and oxidized glutathione (GSSG) levels. Results showed that 44'-BP effectively suppressed the amounts of tyrosinase and MITF proteins, cAMP levels, and PKA activation. In addition, 44'-BP enhanced the GSH/GSSG ratio. In conclusion, our data provide an evidence that 44'-BP suppressed several cellular key parameters in the melanogenic pathway by downregulating the cAMP-dependent PKA signaling pathway and decreasing MITF gene expression (implied from the reduced protein levels), which in turn suppressed tyrosinase. We propose that the antimelanogenic action of 44'-BP is likely carried out by a combined effect of its anti-oxidant property and its ability to enhance intracellular GSH levels.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4,4′-Dihydroxybiphenyl, 97%